Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 09/16/2025 at 12:00, 4 months 14 days ago

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Moderna reports 8-fold increase in neutralizing antibodies with Spikevax 2025-2026 formula, reinforcing FDA approval. Clinical trial data supports efficacy against COVID-19 LP.8.1 variant

FDA Approval COVID-19 Vaccine Moderna Spikevax Neutralizing Antibodies
BRIEF

published on 09/02/2025 at 13:05, 4 months 28 days ago

Moderna to Present mRNA Therapeutics Data at 2025 ICIEM

MRNA Therapeutics Moderna Propionic Acidemia ICIEM Methylmalonic Acidemia
PRESS RELEASE

published on 09/02/2025 at 13:00, 4 months 28 days ago

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
Moderna, Inc. to present abstracts on mRNA therapeutics at the 2025 ICIEM including PA, MMA, and GSD1a programs in Kyoto, Japan. Company's first time presenting data for MMA and GSD1a

Moderna Inc. MRNA Therapeutics ICIEM Abstracts Kyoto Japan
BRIEF

published on 08/27/2025 at 19:29, 5 months 4 days ago

Moderna's Updated COVID-19 Vaccines Approved by U.S. FDA

FDA Approval COVID-19 Vaccine Moderna SARS-CoV-2 Variant Spikevax And MNEXSPIKE
PRESS RELEASE

published on 08/27/2025 at 19:24, 5 months 4 days ago

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
Moderna announces FDA approval for updated Spikevax® and mNEXSPIKE® COVID-19 vaccines targeting LP.8.1 variant to prevent severe outcomes. Vaccines available soon

FDA Approval Moderna COVID-19 Vaccines Spikevax MNEXSPIKE
BRIEF

published on 08/22/2025 at 15:30, 5 months 9 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine

COVID-19 Vaccine Moderna Health Canada Approval Canadian Manufacturing Biomanufacturing Leadership
PRESS RELEASE

published on 08/22/2025 at 15:25, 5 months 9 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna's Spikevax COVID-19 vaccine for SARS-CoV-2 LP.8.1 variant authorized in Canada, with all 2025 doses produced domestically. Leadership in biomanufacturing highlighted

COVID-19 Vaccine Canada Moderna Spikevax Biomanufacturing
BRIEF

published on 08/21/2025 at 13:05, 5 months 10 days ago

Moderna to Participate in Major September 2025 Conferences

Investor Conferences MRNA Medicine Moderna Live Webcast Healthcare Presentation
PRESS RELEASE

published on 08/21/2025 at 13:00, 5 months 10 days ago

Moderna to Present at Upcoming Conferences in September 2025
Moderna, Inc. to participate in upcoming investor conferences. The company's innovative mRNA technology redefines medicine creation, focusing on infectious diseases, oncology, and more

Investor Conferences Healthcare COVID-19 Vaccine MRNA Technology Moderna
BRIEF

published on 08/01/2025 at 13:05, 5 months 30 days ago

Moderna's Q2 2025 Financial Results and Business Updates

Cost Management FDA Approvals Q2 2025 Revenue Moderna Financial Results Vaccine Sales

Published on 01/31/2026 at 03:15, 1 day 5 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 6 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 7 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 9 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 10 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 17 hours 17 minutes ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 20 hours 46 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 6 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 11 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 13 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 17:45, 1 day 15 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 2 days 1 hour ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 2 days 15 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 days 15 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 days 15 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News